Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

522 trials

NCT05833867
Recruiting
Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer
Phase 1 · United States · 1 site
Registry update: 20 Jul 2026
NCT07646145
Recruiting
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2 · China · 1 site
Registry update: 3 Nov 2026
NCT06335667
Recruiting
mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer
Not applicable · United States · 1 site
Registry update: 4 May 2026
NCT06253871
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · Spain, France, United Kingdom, Ireland, Italy, South Korea, Netherlands, United States · 53 sites
Registry update: 9 Sept 2026
NCT06341478
Recruiting
Investigator Grant (IG) 2022 27746
Not applicable · Italy · 1 site
Registry update: 2 Apr 2024
NCT06242470
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · Australia, United Kingdom, United States · 12 sites
Registry update: 28 Oct 2026
NCT06138561
Recruiting
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Not applicable · United States · 1 site
Registry update: 17 Feb 2026
NCT06991868
Recruiting
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
Not applicable · China · 1 site
Registry update: 28 May 2025
NCT06172478
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · Australia, Belgium, Canada, China, Germany, Spain, France, United Kingdom, Hungary, Italy, Japan, South Korea, Netherlands, Norway, Taiwan, United States · 96 sites
Registry update: 26 Oct 2026
NCT06210490
Recruiting
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
Phase 2 · China · 1 site
Registry update: 15 Dec 2025
NCT06269536
Recruiting
Stress-reducing Intervention in Urothelial Carcinoma
Not applicable · Slovakia · 1 site
Registry update: 21 Feb 2024
NCT06293898
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 · United States · 26 sites
Registry update: 13 Oct 2026
NCT06992986
Recruiting
Urinary Microbiome Differences in Bladder Cancer, Benign Urinary Diseases and Healthy Counterparts in Adult Male Population
Not applicable · Italy · 1 site
Registry update: 28 May 2025
NCT05987241
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Phase 2/3 · Canada, United States · 505 sites
Registry update: 6 Nov 2026
NCT06696742
Recruiting
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Phase 2 · China · 1 site
Registry update: 20 Nov 2024
NCT05825950
Recruiting
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Not applicable · United States · 2 sites
Registry update: 24 Aug 2026
NCT06186414
Recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
Phase 1 · China · 14 sites
Registry update: 15 Jan 2025
NCT06310759
Recruiting
Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer
Not applicable · Canada, Finland, Japan, United States · 8 sites
Registry update: 10 Oct 2025
NCT06389019
Recruiting
Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer
Not applicable · China · 1 site
Registry update: 9 Nov 2026
NCT07319923
Recruiting
Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing
Not applicable · China · 1 site
Registry update: 6 Jan 2026

Ordered by registry start date. Freshness and sponsorship never change the order.